CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

Thomas J. Montine, Min Shi, Joseph Quinn, Elaine R. Peskind, Suzanne Craft, Carmen Ginghina, Kathryn (Kathy) Chung, Hojoong Kim, Douglas R. Galasko, Joseph Jankovic, Cyrus P. Zabetian, James B. Leverenz, Jing Zhang

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ42, total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ42 was reduced in PD-CIND (P <0.05) and PD-D (P <0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ42 may be a common feature of PD-CIND and PD-D.

Original languageEnglish (US)
Pages (from-to)2682-2685
Number of pages4
JournalMovement Disorders
Volume25
Issue number15
DOIs
StatePublished - Nov 2010

Fingerprint

Parkinson Disease
Dementia
Alzheimer Disease
Biomarkers
Cognitive Dysfunction
Control Groups

Keywords

  • Cognitive impairment
  • CSF biomarkers
  • Parkinson's disease
  • Tau

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Montine, T. J., Shi, M., Quinn, J., Peskind, E. R., Craft, S., Ginghina, C., ... Zhang, J. (2010). CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Movement Disorders, 25(15), 2682-2685. https://doi.org/10.1002/mds.23287

CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. / Montine, Thomas J.; Shi, Min; Quinn, Joseph; Peskind, Elaine R.; Craft, Suzanne; Ginghina, Carmen; Chung, Kathryn (Kathy); Kim, Hojoong; Galasko, Douglas R.; Jankovic, Joseph; Zabetian, Cyrus P.; Leverenz, James B.; Zhang, Jing.

In: Movement Disorders, Vol. 25, No. 15, 11.2010, p. 2682-2685.

Research output: Contribution to journalArticle

Montine, TJ, Shi, M, Quinn, J, Peskind, ER, Craft, S, Ginghina, C, Chung, KK, Kim, H, Galasko, DR, Jankovic, J, Zabetian, CP, Leverenz, JB & Zhang, J 2010, 'CSF Aβ42 and tau in Parkinson's disease with cognitive impairment', Movement Disorders, vol. 25, no. 15, pp. 2682-2685. https://doi.org/10.1002/mds.23287
Montine TJ, Shi M, Quinn J, Peskind ER, Craft S, Ginghina C et al. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Movement Disorders. 2010 Nov;25(15):2682-2685. https://doi.org/10.1002/mds.23287
Montine, Thomas J. ; Shi, Min ; Quinn, Joseph ; Peskind, Elaine R. ; Craft, Suzanne ; Ginghina, Carmen ; Chung, Kathryn (Kathy) ; Kim, Hojoong ; Galasko, Douglas R. ; Jankovic, Joseph ; Zabetian, Cyrus P. ; Leverenz, James B. ; Zhang, Jing. / CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. In: Movement Disorders. 2010 ; Vol. 25, No. 15. pp. 2682-2685.
@article{07e86365887f43b7a3b159af6d3894be,
title = "CSF Aβ42 and tau in Parkinson's disease with cognitive impairment",
abstract = "We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ42, total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ42 was reduced in PD-CIND (P <0.05) and PD-D (P <0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ42 may be a common feature of PD-CIND and PD-D.",
keywords = "Aβ, Cognitive impairment, CSF biomarkers, Parkinson's disease, Tau",
author = "Montine, {Thomas J.} and Min Shi and Joseph Quinn and Peskind, {Elaine R.} and Suzanne Craft and Carmen Ginghina and Chung, {Kathryn (Kathy)} and Hojoong Kim and Galasko, {Douglas R.} and Joseph Jankovic and Zabetian, {Cyrus P.} and Leverenz, {James B.} and Jing Zhang",
year = "2010",
month = "11",
doi = "10.1002/mds.23287",
language = "English (US)",
volume = "25",
pages = "2682--2685",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "15",

}

TY - JOUR

T1 - CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

AU - Montine, Thomas J.

AU - Shi, Min

AU - Quinn, Joseph

AU - Peskind, Elaine R.

AU - Craft, Suzanne

AU - Ginghina, Carmen

AU - Chung, Kathryn (Kathy)

AU - Kim, Hojoong

AU - Galasko, Douglas R.

AU - Jankovic, Joseph

AU - Zabetian, Cyrus P.

AU - Leverenz, James B.

AU - Zhang, Jing

PY - 2010/11

Y1 - 2010/11

N2 - We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ42, total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ42 was reduced in PD-CIND (P <0.05) and PD-D (P <0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ42 may be a common feature of PD-CIND and PD-D.

AB - We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ42, total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ42 was reduced in PD-CIND (P <0.05) and PD-D (P <0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ42 may be a common feature of PD-CIND and PD-D.

KW - Aβ

KW - Cognitive impairment

KW - CSF biomarkers

KW - Parkinson's disease

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=78349237282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349237282&partnerID=8YFLogxK

U2 - 10.1002/mds.23287

DO - 10.1002/mds.23287

M3 - Article

C2 - 20818673

AN - SCOPUS:78349237282

VL - 25

SP - 2682

EP - 2685

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 15

ER -